marked.bio

multi-kinase inhibitor · small molecule

surufatinib

1 active trials across 7 of our biomarkers, targeting VEGFR/FGFR1/CSF1R. Not approved for any biomarker on marked.bio yet.

Also known as HMPL-012.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 1 Phase 2
BRAF V600E 1 3 Phase 2
EGFR exon 19 deletion / L858R 1 1 Phase 2
MET exon 14 skipping 1 1 Phase 2
NTRK1/2/3 fusion 1 1 Phase 2
RET fusion or mutation 1 1 Phase 2
ROS1 fusion 1 1 Phase 2

Trials

1 of 3 trials shown

  1. Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

    Active, not recruiting Phase 2 Li Zhang, MD Started 2022Primary completion 2025-11 NCT05003037

    surufatinibtoripalimabpemetrexedcarboplatincisplatin

    EGFR mutation cases are not expected to exceed 50% of all enrolled patients in Cohort 2.

    EGFR exon 19 deletion / L858RBRAF V600EMET exon 14 skippingALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusionNon Small Cell Lung Cancer